<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE book-part-wrapper PUBLIC "-//NLM//DTD BITS Book Interchange DTD v2.0 20151225//EN" "http://jats.nlm.nih.gov/extensions/bits/2.0/BITS-book2.dtd">
<book-part-wrapper id="Efgartigimod" content-type="chapter" from-where="body" dtd-version="2.0">
  <book-meta>
    <book-id book-id-type="pmcid">livertox</book-id>
    <book-title-group>
      <book-title>LiverTox</book-title>
      <subtitle>Clinical and Research Information on Drug-Induced Liver Injury</subtitle>
    </book-title-group>
    <pub-date date-type="pubr" publication-format="electronic">
      <year>2012</year>
    </pub-date>
    <publisher>
      <publisher-name>National Institute of Diabetes and Digestive and Kidney Diseases</publisher-name>
      <publisher-loc>Bethesda (MD)</publisher-loc>
    </publisher>
    <custom-meta-group>
      <custom-meta>
        <meta-name>books-source-type</meta-name>
        <meta-value>Database</meta-value>
      </custom-meta>
    </custom-meta-group>
  </book-meta>
  <book-part book-part-type="chapter">
    <book-part-meta>
      <book-part-id book-part-id-type="pmcid">Efgartigimod</book-part-id>
      <title-group>
        <title>Efgartigimod alfa, alfa/Hyaluronidase</title>
      </title-group>
      <pub-history>
        <date date-type="updated">
          <day>2</day>
          <month>2</month>
          <year>2025</year>
        </date>
      </pub-history>
      <related-object link-type="parent-book-link" source-id="livertox">LiverTox: Clinical and Research Information on Drug-Induced Liver Injury</related-object>
      <related-object link-type="previous-part-link" source-id="livertox" document-id="Efavirenz" document-type="chapter">Efavirenz</related-object>
      <related-object link-type="next-part-link" source-id="livertox" document-id="Elacestrant" document-type="chapter">Elacestrant</related-object>
    </book-part-meta>
    <body>
      <sec id="Efgartigimod.OVERVIEW">
        <title>OVERVIEW</title>
        <sec id="Efgartigimod.Introduction" sec-type="pubmed-excerpt">
          <title>Introduction</title>
          <p>Efgartigimod alfa is a neonatal Fc receptor blocker that is used in the treatment of adults with generalized myasthenia gravis who test positive for anti-acetylcholine receptor antibody. Efgartigimod alfa has not been associated with elevations in serum aminotransferase levels or with cases of clinically apparent liver injury.</p>
        </sec>
        <sec id="Efgartigimod.Background">
          <title>Background</title>
          <p>Efgartigimod alfa (ef&#x0201d; gar tig&#x02019; i mod) is a modified, recombinant human IgG1 Fc fragment that binds to the neonatal Fc receptor site on cell surface membranes and prevents immunoglobulin G (IgG) recycling, thus increasing rates of IgG degradation without affecting its production or function. Efgartigimod decreases levels of IgG in the circulation which particularly affects autoantibody levels. Efgartigimod has been evaluated as therapy of several autoimmune diseases but was initially approved only for adults with myasthenia gravis. Myasthenia gravis is a rare autoimmune neuromuscular disease which is characterized by autoantibodies to the acetylcholine receptor. These autoantibodies block acetylcholine neurotransmission and result in weakness in skeletal muscles, particularly those of the eye, face, throat, and limbs. Myasthenia gravis is typically treated with anticholinesterases which prolonged acetylcholine actions, but which are usually only partly effective. Other agents used off label include corticosteroids, azathioprine, tacrolimus, methotrexate, and rituximab. Eculizumab, a monoclonal antibody to complement factor 5, was approved for use in refractory myasthenia gravis in 2017. Efgartigimod alfa was evaluated in adults with refractory myasthenia gravis and found to lead to improvements in muscle function in a high proportion of patients. Efgartigimod alfa was granted accelerated approval for use in myasthenia gravis in the United States in 2021. Current indications are limited to adults who are positive for anti-acetylcholine antibodies (found in 80 to 90% of patients). Efgartigimod alfa is available in solution in single dose vials of 400 mg/20 mL [20 mg/mL] under the brand name Vyvgart. The recommended dose regimen is 10 mg/kg given iv over one hour once weekly for 4 weeks, with further 4-week cycles based upon efficacy and tolerance. In 2023, the combination of efgartigimod alfa with hyaluronidase, which allows for subcutaneous administration, was approved for the same indication, available in single dose vials of 1008 mg of efgartigimod alfa and 11,200 units of hyaluronidase under the brand name Vyvgart Hytrulo. The recommended regimen is one vial given sc in cycles of once weekly for 4 weeks. Common side effects of efgartigimod alfa include headaches, urinary and respiratory tract infections, myalgia, paresthesia, and hematologic adverse reactions. Uncommon but potentially serious adverse events included infusion reactions, hypersensitivity reactions and infections. The two formulations of efgartigimod alfa have similar profiles of adverse events except for types of injection site reactions.</p>
        </sec>
        <sec id="Efgartigimod.Hepatotoxicity">
          <title>Hepatotoxicity</title>
          <p>In the registration studies submitted in support of approval of efgartigimod alfa, there were no serum ALT or AST elevations above 3 times the upper limit of normal (ULN) and no patient developed serum enzyme elevations and jaundice or evidence of clinically apparent liver injury. Since its approval and more widespread use including controlled trials of both intravenous and subcutaneous forms of efgartigimod, there has been no reports of clinically apparent liver injury attributed to their use.</p>
          <p>Likelihood score: E (unlikely cause of clinically apparent liver injury).</p>
        </sec>
        <sec id="Efgartigimod.Mechanism_of_Injury">
          <title>Mechanism of Injury</title>
          <p>The mechanism by which efgartigimod alfa alone or in combination with hyaluronidase might cause liver injury is unknown. Efgartigimod alfa is a polypeptide and is metabolized by proteolysis into individual amino acids in cells. Efgartigimod alfa is not metabolized by the cytochrome P450 system and has not been associated with drug-drug interactions. Possible exceptions, however, might be agents that can bind to the human neonatal Fc receptor such as monoclonal antibodies and immunoglobulin products.</p>
        </sec>
        <sec id="Efgartigimod.Outcome_and_Management">
          <title>Outcome and Management</title>
          <p>Efgartigimod alfa and efgartigimod alfa/hyaluronidase have not been implicated in significant serum aminotransferase elevations or instances of acute liver injury. While minor elevations in serum enzymes may occur during therapy, these are generally transient, asymptomatic, and most likely unrelated to treatment .</p>
          <p>Drug Class: Myasthenia Agents</p>
          <p>Other Drugs in for Myasthenia Gravis: <related-object link-type="booklink" source-id="livertox" document-id="Eculizumab" document-type="book-part">Eculizumab</related-object>, Pyridostigmine</p>
        </sec>
      </sec>
      <sec id="Efgartigimod.PRODUCT_INFORMATION">
        <title>PRODUCT INFORMATION</title>
        <p>
<bold>REPRESENTATIVE TRADE NAMES</bold>
</p>
        <p>Efgartigimod alfa &#x02013; Vyvgart&#x000ae;</p>
        <p>Efgartigimod alfa/Hyaluronidase &#x02013; Vyvgart Hytrulo&#x000ae;</p>
        <p>
<bold>DRUG CLASS</bold>
</p>
        <p>Myasthenia Agents</p>
        <p><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://dailymed.nlm.nih.gov/dailymed/search.cfm?labeltype=all&#x00026;query=Efgartigimod%20alfa">COMPLETE LABELING</ext-link> [E. alfa]</p>
        <p><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://dailymed.nlm.nih.gov/dailymed/search.cfm?labeltype=all&#x00026;query=Efgartigimod%20alfa/Hyaluronidase">COMPLETE LABELING</ext-link> [E. alfa/hyaluronidase]</p>
        <p>Product labeling at DailyMed, National Library of Medicine, NIH</p>
      </sec>
      <sec id="Efgartigimod.CHEMICAL_FORMULA_AND_STRUCT">
        <title>CHEMICAL FORMULA AND STRUCTURE</title>
        <table-wrap id="Efgartigimod.Tc" orientation="portrait" position="anchor">
          <table frame="hsides" rules="groups">
            <thead>
              <tr>
                <th id="hd_h_Efgartigimod.Tc_1_1_1_1" valign="top" align="left" scope="col" rowspan="1" colspan="1">DRUG</th>
                <th id="hd_h_Efgartigimod.Tc_1_1_1_2" valign="top" align="left" scope="col" rowspan="1" colspan="1">CAS REGISTRY NUMBER</th>
                <th id="hd_h_Efgartigimod.Tc_1_1_1_3" valign="top" align="left" scope="col" rowspan="1" colspan="1">MOLECULAR FORMULA</th>
                <th id="hd_h_Efgartigimod.Tc_1_1_1_4" valign="top" align="left" scope="col" rowspan="1" colspan="1">STRUCTURE</th>
              </tr>
            </thead>
            <tbody>
              <tr>
                <td headers="hd_h_Efgartigimod.Tc_1_1_1_1" valign="top" align="left" scope="row" rowspan="1" colspan="1">Efgartigimod alfa</td>
                <td headers="hd_h_Efgartigimod.Tc_1_1_1_2" valign="top" align="left" rowspan="1" colspan="1">
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pubchem" xlink:href="sid://381128075">1821402-21-4</ext-link>
</td>
                <td headers="hd_h_Efgartigimod.Tc_1_1_1_3" valign="top" align="left" rowspan="1" colspan="1">C2310-H3554-N602-O692-S14</td>
                <td headers="hd_h_Efgartigimod.Tc_1_1_1_4" valign="top" align="left" rowspan="1" colspan="1">Not Available</td>
              </tr>
            </tbody>
          </table>
        </table-wrap>
      </sec>
      <sec id="Efgartigimod.ANNOTATED_BIBLIOGRAPHY">
        <title>ANNOTATED BIBLIOGRAPHY</title>
        <p>References updated: 02 February 2025</p>
        <p>Abbreviations: iv, intravenous; sc, subcutaneous; ULN, upper limit of normal.</p>
        <ref-list id="Efgartigimod.ANNOTATED_BIBLIOGRAPHY.reflist0">
          <ref id="Efgartigimod.REF.zimmerman.1999">
            <mixed-citation publication-type="book">Zimmerman HJ. In, Zimmerman HJ. Hepatotoxicity: the adverse effects of drugs and other chemicals on the liver. 2nd ed. Philadelphia: Lippincott, 1999.<annotation><p><italic toggle="yes">(Expert textbook on hepatotoxicity published in 1999, before the availability of efgartigimod alfa).</italic></p></annotation></mixed-citation>
          </ref>
          <ref id="Efgartigimod.REF2">
            <mixed-citation publication-type="web">FDA. Integrated Review. 2021. <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.accessdata.fda.gov/drugsatfda_docs/nda/2022/761195Orig1s000IntegratedR.pdf">https://www.accessdata.fda.gov/drugsatfda_docs/nda/2022/761195Orig1s000IntegratedR.pdf</ext-link><annotation><p><italic toggle="yes">(FDA website with product labels and integrated review of efficacy and safety data on efgartigimod submitted by the sponsor in support of approval in the US, mentions that in the safety database of 246 subjects, adverse events more frequent with efgartigimod vs placebo included urinary tract infections, myalgia, paresthesia, respiratory tract infections, and headache, and that no participant developed ALT or AST elevations above 3 times ULN or any elevations with bilirubin above twice normal).</italic></p></annotation></mixed-citation>
          </ref>
          <ref id="Efgartigimod.REF.howard.2019.e2661">
            <mixed-citation publication-type="journal"><string-name name-style="western"><surname>Howard</surname>
<given-names>JF</given-names>
<suffix>Jr</suffix></string-name>, <string-name name-style="western"><surname>Bril</surname>
<given-names>V</given-names></string-name>, <string-name name-style="western"><surname>Burns</surname>
<given-names>TM</given-names></string-name>, <string-name name-style="western"><surname>Mantegazza</surname>
<given-names>R</given-names></string-name>, <string-name name-style="western"><surname>Bilinska</surname>
<given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Szczudlik</surname>
<given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Beydoun</surname>
<given-names>S</given-names></string-name>, <etal>et al.</etal>; <article-title>Efgartigimod MG Study Group. Randomized phase 2 study of FcRn antagonist efgartigimod in generalized myasthenia gravis.</article-title>
<source>Neurology.</source>
<year>2019</year>;<volume>92</volume>:<fpage>e2661</fpage>-<lpage>e2673</lpage>.<annotation><p><italic toggle="yes">(Among 24 adults with myasthenia gravis treated with efgartigimod [10 mg/kg] or placebo given iv in 4 weekly doses, there was a rapid decrease in total IgG [-40%] and anti-acetylcholine receptor antibodies with efgartigimod treatment, and adverse event rates were 83% in both groups; no mention of ALT elevations or hepatotoxicity).</italic></p></annotation><pub-id pub-id-type="pmid">31118245</pub-id>
</mixed-citation>
          </ref>
          <ref id="Efgartigimod.REF.howard.2021.526">
            <mixed-citation publication-type="journal"><string-name name-style="western"><surname>Howard</surname>
<given-names>JF</given-names>
<suffix>Jr</suffix></string-name>, <string-name name-style="western"><surname>Bril</surname>
<given-names>V</given-names></string-name>, <string-name name-style="western"><surname>Vu</surname>
<given-names>T</given-names></string-name>, <string-name name-style="western"><surname>Karam</surname>
<given-names>C</given-names></string-name>, <string-name name-style="western"><surname>Peric</surname>
<given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Margania</surname>
<given-names>T</given-names></string-name>, <string-name name-style="western"><surname>Murai</surname>
<given-names>H</given-names></string-name>, <etal>et al.</etal>; <collab>ADAPT Investigator Study Group</collab>. <article-title>Safety, efficacy, and tolerability of efgartigimod in patients with generalized myasthenia gravis (ADAPT): a multicentre, randomised, placebo-controlled, phase 3 trial.</article-title>
<source>Lancet Neurol.</source>
<year>2021</year>;<volume>20</volume>:<fpage>526</fpage>-<lpage>536</lpage>.<annotation><p><italic toggle="yes">(Among 167 adults with myasthenia gravis treated with efgartigimod [10 mg/kg] vs placebo iv in cycles of 4 weekly iv infusions, response rates were 68% vs 30% with the first cycle and adverse event rates 77% vs 84% which were serious in 5% vs 8%, and &#x0201c;there were no clinically meaningful changes in haematology or chemistry parameters&#x0201d;).</italic></p></annotation><pub-id pub-id-type="pmid">34146511</pub-id>
</mixed-citation>
          </ref>
          <ref id="Efgartigimod.REF5">
            <mixed-citation publication-type="journal"><article-title>Efgartigimod alfa (Vyvgart) for myasthenia gravis.</article-title>
<source>Med Lett Drugs Ther.</source>
<year>2022</year>;<volume>64</volume>:<fpage>62</fpage>-<lpage>63</lpage>.<annotation><p><italic toggle="yes">(Concise review of the mechanism of action, clinical efficacy, safety, and costs of efgartigimod alfa shortly after its approval for use in myasthenia gravis in the US, mentions common adverse events of headache, respiratory and urinary tract infections, paresthesia, myalgia, and hematologic abnormalities; no mention of ALT elevations or hepatotoxicity).</italic></p></annotation><pub-id pub-id-type="pmid">35436776</pub-id>
</mixed-citation>
          </ref>
          <ref id="Efgartigimod.REF.broome.2023.1648">
            <mixed-citation publication-type="journal"><string-name name-style="western"><surname>Broome</surname>
<given-names>CM</given-names></string-name>, <string-name name-style="western"><surname>McDonald</surname>
<given-names>V</given-names></string-name>, <string-name name-style="western"><surname>Miyakawa</surname>
<given-names>Y</given-names></string-name>, <string-name name-style="western"><surname>Carpenedo</surname>
<given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Kuter</surname>
<given-names>DJ</given-names></string-name>, <string-name name-style="western"><surname>Al-Samkari</surname>
<given-names>H</given-names></string-name>, <string-name name-style="western"><surname>Bussel</surname>
<given-names>JB</given-names></string-name>
<etal>et al.</etal>; <collab>ADVANCE Investigator Study Group</collab>. <article-title>Efficacy and safety of the neonatal Fc receptor inhibitor efgartigimod in adults with primary immune thrombocytopenia (ADVANCE IV): a multicentre, randomised, placebo-controlled, phase 3 trial.</article-title>
<source>Lancet.</source>
<year>2023</year>;<volume>402</volume>(<issue>10413</issue>):<fpage>1648</fpage>-<lpage>1659</lpage>.<annotation><p><italic toggle="yes">(Among 131 adults with primary immune thrombocytopenia treated with efgartigimod [10 mg/kg] or placebo in weekly iv infusions, clinical responses occurred in 22% vs 5% and adverse events in 93% vs 96% which were serious in 8% vs 16%; no mention of ALT elevations or hepatotoxicity).</italic></p></annotation><pub-id pub-id-type="pmid">37778358</pub-id>
</mixed-citation>
          </ref>
          <ref id="Efgartigimod.REF.howard.2024.1284444">
            <mixed-citation publication-type="journal"><string-name name-style="western"><surname>Howard</surname>
<given-names>JF</given-names>
<suffix>Jr</suffix></string-name>, <string-name name-style="western"><surname>Bril</surname>
<given-names>V</given-names></string-name>, <string-name name-style="western"><surname>Vu</surname>
<given-names>T</given-names></string-name>, <string-name name-style="western"><surname>Karam</surname>
<given-names>C</given-names></string-name>, <string-name name-style="western"><surname>Peric</surname>
<given-names>S</given-names></string-name>, <string-name name-style="western"><surname>De Bleecker</surname>
<given-names>JL</given-names></string-name>, <string-name name-style="western"><surname>Murai</surname>
<given-names>H</given-names></string-name>, <etal>et al.</etal>; <article-title>ADAPT+ Study Group. Long-term safety, tolerability, and efficacy of efgartigimod (ADAPT+): interim results from a phase 3 open-label extension study in participants with generalized myasthenia gravis.</article-title>
<source>Front Neurol.</source>
<year>2024</year>;<volume>14</volume>:<elocation-id>1284444</elocation-id>.<annotation><p><italic toggle="yes">(Among 151 adults with myasthenia gravis enrolled in a long term,, open label extension study of efgartigimod alfa given in cycles of 4 weekly iv infusions [10 mg/kg], clinical responses were maintained and adverse events were mostly mild-to-moderate, resulted in discontinuation in 8%, and fatality in 5, none of which were considered drug- or liver related; no mention of ALT elevations or hepatotoxicity).</italic></p></annotation><pub-id pub-id-type="pmid">38318236</pub-id>
</mixed-citation>
          </ref>
          <ref id="Efgartigimod.REF.howard.2024.e00378">
            <mixed-citation publication-type="journal"><string-name name-style="western"><surname>Howard</surname>
<given-names>JF</given-names>
<suffix>Jr</suffix></string-name>, <string-name name-style="western"><surname>Vu</surname>
<given-names>T</given-names></string-name>, <string-name name-style="western"><surname>Li</surname>
<given-names>G</given-names></string-name>, <string-name name-style="western"><surname>Korobko</surname>
<given-names>D</given-names></string-name>, <string-name name-style="western"><surname>Smilowski</surname>
<given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Liu</surname>
<given-names>L</given-names></string-name>, <string-name name-style="western"><surname>Gistelinck</surname>
<given-names>F</given-names></string-name>, <etal>et al.</etal>; <article-title>ADAPT-SC and ADAPT-SC+ Study Groups. Subcutaneous efgartigimod PH20 in generalized myasthenia gravis: A phase 3 randomized noninferiority study (ADAPT-SC) and interim analyses of a long-term open-label extension study (ADAPT-SC+).</article-title>
<source>Neurotherapeutics.</source>
<year>2024</year>;<volume>21</volume>:<elocation-id>e00378</elocation-id>.<annotation><p><italic toggle="yes">(Among 145 adults with myasthenia gravis enrolled in an extended open label trial of efgartigimod alfa/hyaluronidase in cycles of 10 mg/kg given sc weekly for 4 weeks [average duration 569 days and up to 17 cycles], adverse events arose in 85%, most frequent symptoms being headache, COVID-19, diarrhea, urinary and respiratory tract infections, fever, nausea, hypertension, and oropharyngeal pain, and &#x0201c;there were no clinically relevant changes from baseline in hematology and chemistry parameters&#x0201d;).</italic></p></annotation><pub-id pub-id-type="pmid">39227284</pub-id>
</mixed-citation>
          </ref>
          <ref id="Efgartigimod.REF.allen.2024.1013">
            <mixed-citation publication-type="journal"><string-name name-style="western"><surname>Allen</surname>
<given-names>JA</given-names></string-name>, <string-name name-style="western"><surname>Lin</surname>
<given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Basta</surname>
<given-names>I</given-names></string-name>, <string-name name-style="western"><surname>Dysgaard</surname>
<given-names>T</given-names></string-name>, <string-name name-style="western"><surname>Eggers</surname>
<given-names>C</given-names></string-name>, <string-name name-style="western"><surname>Guptill</surname>
<given-names>JT</given-names></string-name>, <string-name name-style="western"><surname>Gwathmey</surname>
<given-names>KG</given-names></string-name>, <etal>et al.</etal>; <collab>ADHERE Study Group</collab>. <article-title>Safety, tolerability, and efficacy of subcutaneous efgartigimod in patients with chronic inflammatory demyelinating polyradiculoneuropathy (ADHERE): a multicentre, randomised-withdrawal, double-blind, placebo-controlled, phase 2 trial.</article-title>
<source>Lancet Neurol.</source>
<year>2024</year>;<volume>23</volume>:<fpage>1013</fpage>-<lpage>1024</lpage>.<annotation><p><italic toggle="yes">(Among 221 adults with chronic inflammatory demyelinating polyradiculoneuropathy treated with efgartigimod alfa/hyaluronidase or placebo sc once weekly for 4 weeks, relapses were less frequent with efgartigimod [28% vs 56%], while adverse events arose in 64% vs 56% and severe adverse events in 5% vs 5%; no mention of ALT elevations or hepatotoxicity).</italic></p></annotation><pub-id pub-id-type="pmid">39304241</pub-id>
</mixed-citation>
          </ref>
        </ref-list>
      </sec>
      <sec sec-type="link-group" id="Efgartigimod.OTHER_REFERENCE_LINKS">
        <title>OTHER REFERENCE LINKS</title>
        <p>1. <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.ncbi.nlm.nih.gov/sites/entrez?cmd=search&#x00026;db=pubmed&#x00026;pubmedfilters=true&#x00026;term=(Efgartigimod+alfa/AE)+AND+Human%5BMH%5D+AND+(drug+induced+liver+injury+OR+jaundice/CI+OR+bile+duct+diseases/CI+OR+liver/DE+OR+liver+diseases/CI)+AND+(%221900/1/1%22%5BEDat%5D:%222999/12/31%22%5BEDat%5D)">Recent References on Efgartigimod alfa: from PubMed.gov</ext-link></p>
        <p>2. <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://clinicaltrials.gov/ct2/results?term=Efgartigimod%20alfa">Trials on Efgartigimod alfa: from ClinicalTrials.gov</ext-link></p>
      </sec>
    </body>
  </book-part>
</book-part-wrapper>
